2,379 results on '"Therapeutic plasma exchange"'
Search Results
2. Clinical application of centrifugal‐membrane hybrid plasmapheresis in the treatment of hyperlipidemia.
- Author
-
Yi, Zhongmei, Wu, Chunxi, Zhou, Yumeng, and Zhang, Bin
- Abstract
Objective Methods Results Conclusion This study aimed to clarify the clinical application of centrifugal‐membrane hybrid plasmapheresis (CMHP) in the treatment of hyperlipidemia.A retrospective study was conducted on 48 patients who were diagnosed with hyperlipidemia and had received CMHP treatment. Serum total cholesterol (TC), triglycerides (TG), high‐density lipoprotein cholesterol (HDL‐C), and low‐density lipoprotein cholesterol (LDL‐C) were monitored, and adverse reactions to the treatment were observed.Forty‐eight patients with hyperlipidemia received CMHP over 59 sessions. The average age of the 48 patients with hyperlipidemia, including 32 males (66.67%) and 16 females (33.33%), was 44.23 ± 12.02 years. Twenty‐nine outpatients (60.42%) and 19 inpatients (39.58%) were included. Hypertriglyceridemia was diagnosed in 16 cases (33.33%), mixed hyperlipidemia in 31 cases (64.58%), and hypercholesterolemia in one case (2.08%). The pretreatment blood lipid concentrations were significantly different after the 59 CMHP treatments (p < .001). The concentrations of TC, TG, HDL‐C, and LDL‐C decreased significantly after the treatment, and the median ratios of reduction were 67.06% (range: 58.97%–71.87%), 63.33% (range: 55.20%–74.86%), 45.87% (range: 35.86%–52.95%), and 66.09% (range: 44.37%–73.94%), respectively. Three adverse reactions (5.08%) were recorded. No differences were detected in therapeutic parameters, effects, or adverse reactions between the two blood cell separators, there was no difference in Lipoprotein apheresis efficacy.This preliminary study demonstrated the clinical application of CMHP in patients in the treatment of hyperlipidemia. However, further studies are needed applying CMHP with hyperlipidemia. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Diagnosis and management of pediatric acute liver failure: consensus recommendations of the Indian Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ISPGHAN).
- Author
-
Lal, Bikrant Bihari, Khanna, Rajeev, Sood, Vikrant, Alam, Seema, Nagral, Aabha, Ravindranath, Aathira, Kumar, Aditi, Deep, Akash, Gopan, Amrit, Srivastava, Anshu, Maria, Arjun, Pawaria, Arti, Bavdekar, Ashish, Sindwani, Gaurav, Panda, Kalpana, Kumar, Karunesh, Sathiyasekaran, Malathi, Dhaliwal, Maninder, Samyn, Marianne, and Peethambaran, Maya
- Abstract
Timely diagnosis and management of pediatric acute liver failure (PALF) is of paramount importance to improve survival. The Indian Society of Pediatric Gastroenterology, Hepatology, and Nutrition invited national and international experts to identify and review important management and research questions. These covered the definition, age appropriate stepwise workup for the etiology, non-invasive diagnosis and management of cerebral edema, prognostic scores, criteria for listing for liver transplantation (LT) and bridging therapies in PALF. Statements and recommendations based on evidences assessed using the modified Grading of Recommendations Assessment, Development and Evaluation (GRADE) system were developed, deliberated and critically reappraised by circulation. The final consensus recommendations along with relevant published background information are presented here. We expect that these recommendations would be followed by the pediatric and adult medical fraternity to improve the outcomes of PALF patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Comparative analysis of therapeutic plasma exchange vs. standard management in hypertriglyceridemia-induced acute pancreatitis: triglyceride reduction and clinical outcomes.
- Author
-
Gulumsek, Erdinc, Yigitdol, Ismail, Ozturk, Huseyin Ali, Arici, Fatih Necip, Saler, Tayyibe, and Sumbul, Hilmi Erdem
- Abstract
Background and aim: The use of therapeutic plasma exchange (TPE) for treatment of hypertriglyceridemia-induced acute pancreatitis (HTGP) remains controversial in the literature. This study compared the clinical outcomes of TPE versus conventional therapy in patients with HTGP. Methods: Fifty-five patients with HTGP were included. Patients were retrospectively compared in pairs: those who received TPE treatment and those who did not, those whose triglyceride level fell below 500 mg/dL within 48 h, and those who did not, those with and without persistent organ failure. The primary outcome was the percentage of triglyceride reduction within 48 h. Secondary outcomes were the length of hospital stay, mortality, cost-effectiveness, and persistent organ failure. Results: Percentage decrease in triglyceride levels, medical hospitalization costs, and length of hospital stay were higher in the TPE group compared to the non-TPE group (p < 0.05, for each). However, there was no difference regarding persistent organ failure and mortality (p > 0.05, for each). The length of hospital stay, average cost, persistent organ failure, and mortality were similar in both groups whose triglyceride level fell below 500 mg/dL within 48 h and those who did not (p > 0.05, for each). Among patients with persistent organ failure, average cost was higher in the TPE group compared to the non-TPE group (p < 0.05). An independent relation was found between the average cost and persistent organ failure, TPE, length of hospital stay, albumin, and urea values in all patients (p < 0.05, for each). Conclusions: The approach of using TPE for treatment of HTGP was not found to be superior to the conventional treatment. Randomized controlled studies with larger number of patients are needed to gain better understanding of this issue. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Efficiency of therapeutic plasma exchange in critically ill systemic rheumatologic diseases: A single‐center 9‐year experience.
- Author
-
Guo, Jing, Huang, Xiaolong, Li, Jianhua, Zhang, Xiaorong, Zhong, Ping, Lu, Guiyang, Wang, Xinxin, Luo, Weiyuan, and Ning, Yaogui
- Subjects
PLASMA exchange (Therapeutics) ,CRITICALLY ill ,INTENSIVE care units ,SOFT tissue injuries ,TREATMENT effectiveness - Abstract
Introduction: Therapeutic plasma exchange (TPE), an effective method to eliminate harmful soluble mediators associated with tissue injury, serves as a crucial intervention for systemic rheumatologic diseases (SRDs). However, its value in critically ill SRDs remains uncertain. This retrospective study aims to evaluate the efficacy of TPE in SRDs. Methods: Critically ill SRD patients admitted to the department of intensive care unit of a large tertiary hospital receiving TPE from January 2011 to December 2019 were included. Results: A total of 91 critically ill SRD patients received TPE were enrolled. Their mean age was 47.67 ± 16.35 years with a female predominance (n = 68). Significant decrease in SOFA score post‐TPE treatment was observed (p < 0.05). There were no TPE‐related fatalities. Improvement was observed in 64 (70.32%) patients. Conclusion: This study shows favorable clinical outcomes. TPE may be an acceptable treatment option for critically ill SRD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Therapeutic plasma exchange in critically ill children: A single center experience.
- Author
-
Yazici Özkaya, Pinar, Koç, Gülizar, Ersayoğlu, İrem, Cebeci, Kübra, Hekimci Özdemir, Hamiyet, Karadas, Nihal, Yilmaz Karapinar, Deniz, and Karapinar, Bülent
- Subjects
CRITICALLY ill children ,PLASMA exchange (Therapeutics) ,CHILD patients ,PEDIATRIC intensive care ,HEMOPHAGOCYTIC lymphohistiocytosis - Abstract
Introduction: Therapeutic plasma exchange (TPE) is used in a wide spectrum of diseases in critically ill pediatric patients. We aim to review the indications, complications, safety, and outcomes of critically ill children who received TPE. Methods: All of the TPE procedures performed in a pediatric intensive care unit providing tertiary care during 19 years (January 2013–January 2023) were evaluated retrospectively. A total of 154 patients underwent 486 TPE sessions. Results: Median age was 6 years (2–12.5) and 35 children had a body weight of <10 kg (22.7%). Number of organ failure was 4 (2–6). Liver diseases were the most common indication for TPE (31.2%) followed by sepsis with multiorgan dysfunction syndrome (27.3%). Overall survival rate was 72.7%. The highest mortality was observed in hemophagocytic lymphohistiocytosis group. Non‐survivors had significantly higher number of organ failure (p < 0.001), higher PRISM score (p < 0.001), and higher PELOD score on admission (p < 0.001). Adverse events were observed in 68 (13.9%) sessions. Hypotension (7.8%) and hypocalcemia (5.1%) were the most frequent adverse events. Conclusion: TPE is safe for critically ill pediatric patients with experienced staff. Survival rate may vary depending on the underlying disease. Survival decreases with the increase in the number of failed organs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. A simple predictor for donor‐specific anti‐HLA antibody desensitisation in haploidentical haematopoietic stem cell transplantation.
- Author
-
Li, Jia‐Ming, Zhang, Zi‐Lu, Zhao, Jia‐Lu, Wang, Yu‐Qing, Gong, Song‐Song, Lei, Hang, Wang, Xue‐Feng, Hu, Xiao‐Xia, and Cai, Xiao‐Hong
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *PLASMA exchange (Therapeutics) , *OVERALL survival , *FLUORESCENCE , *IMMUNOTHERAPY - Abstract
Donor‐specific HLA antibody (DSA) has been recognised as an independent risk factor for graft failure in patients undergoing haploidentical haematopoietic stem cell transplantation (HID HSCT). Therapeutic plasma exchange (TPE), as a first‐line strategy for DSA desensitisation, can promptly reduce serum DSA levels. This study aimed to investigate DSA characteristics and identify a biomarker predicting the efficacy of DSA desensitisation in patients proceeding to HID HSCT. We retrospectively enrolled 32 patients with DSA from April 2021 to January 2024, and analysed the mean fluorescence intensity (MFI) value of DSA at the different time points of desensitisation treatment. Compared with baseline DSA level before TPE, the median MFI of HLA class I DSA was reduced from 8178.6 to 795.3 (p < 0.001), and HLA class II DSA decreased from 6210.9 to 808.8 (p < 0.001) after TPE. The DSA level in 1:16 diluted pre‐TPE serum correlated well with DSA value in post‐TPE serum (class I, r = 0.85, p < 0.0001; class II, r = 0.94, p < 0.0001), predicting TPE efficacy in 84.4% of patients. Based on the degree of DSA reduction after TPE, patients were divided into complete responders (decreased by >70%), partial responders (decreased by 30 to 70%) and non‐responders (decreased by <30%) and the percentages were 43.8%, 25% and 31.2%, respectively. Non‐responders receiving aggressive immunotherapy had longer overall survival compared to those receiving standard strategies (p < 0.05). The 1:16 diluted pre‐TPE serum may predict the efficacy of TPE and allow for more rational immunotherapy strategy for patients with DSA proceeding to HID HSCT. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Continuous renal replacement therapy and therapeutic plasma exchange in pediatric liver failure.
- Author
-
Jackson, Caroline, Carlin, Kristen, Blondet, Niviann, Jordan, Ian, Yalon, Larissa, Healey, Patrick J., Symons, Jordan M., and Menon, Shina
- Subjects
- *
PLASMA exchange (Therapeutics) , *RENAL replacement therapy , *LIVER failure , *HEPATIC encephalopathy , *CHILD patients , *BILIARY atresia - Abstract
Patients with acute liver failure (ALF) and acute on chronic liver failure (ACLF) have significant morbidity and mortality. They require extracorporeal blood purification modalities like continuous renal replacement therapy (CRRT) and therapeutic plasma exchange (TPE) as a bridge to recovery or liver transplantation. Limited data are available on the outcomes of patients treated with these therapies. This is a retrospective single-center study of 23 patients from 2015 to 2022 with ALF/ACLF who underwent CRRT and TPE. We aimed to describe the clinical characteristics and outcomes of these patients. Median (IQR) age was 0.93 years (0.57, 9.88), range 16 days to 20 years. Ten (43%) had ALF and 13 (57%) ACLF. Most (n = 19, 82%) started CRRT for hyperammonemia and/or hepatic encephalopathy and all received TPE for refractory coagulopathy. CRRT was started at a median of 2 days from ICU admission, and TPE started on the same day in most. The liver transplant was done in 17 (74%), and 2 recovered native liver function. Four patients, all with ACLF, died prior to ICU discharge without a liver transplant. The median peak ammonia pre-CRRT was 131 µmol/L for the whole cohort. The mean (SD) drop in ammonia after 48 h of CRRT was 95.45 (43.72) µmol/L in those who survived and 69.50 (21.70) µmol/L in those who did not (p 0.26). Those who survived had 0 median co-morbidities compared to 2.5 in non-survivors (aOR (95% CI) for mortality risk of 2.5 (1.1–5.7), p 0.028). Conclusion: In this cohort of 23 pediatric patients with ALF or ACLF who received CRRT and TPE, 83% survived with a liver transplant or recovered with their native liver. Survival was worse in those who had ACLF and those with co-morbid conditions. What is Known: • Pediatric acute liver failure is associated with high mortality. • Patients may require extracorporeal liver assist therapies (like CRRT, TPE, MARS, SPAD) to bridge them over to a transplant or recovery of native liver function. What is New: • Standard volume plasma exhange has not been evaluated against high volume plasma exchange for ALF. • The role, dose, and duration of therapeutic plasma exchange in patients with acute on chronic liver failure is not well described. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Therapeutic plasma exchange for sickle cell disease acute complications: A systematic review.
- Author
-
Denoon, Romario B., Soares Ferreira Junior, Alexandre, Tuttle, Brandi, and Onwuemene, Oluwatoyosi A.
- Subjects
- *
HEMAPHERESIS , *GALLSTONES , *THROMBOTIC thrombocytopenic purpura , *MYOCARDIAL infarction , *ACUTE phase proteins , *HEPATORENAL syndrome , *LEG pain - Abstract
This article is a systematic review of the use of therapeutic plasma exchange (TPE) for acute complications of sickle cell disease (SCD). The review found that TPE may provide benefits by removing inflammatory cytokines and plasma-based acute phase proteins. The review analyzed studies on TPE for multi-organ failure, thrombotic microangiopathy, intrahepatic cholestasis, and other indications. More evidence is needed to fully understand the impact of TPE on patient outcomes. The text provides a series of case studies on patients with sickle cell disease who underwent TPE as a treatment. TPE was found to improve hemodynamic and respiratory status, resolve organ dysfunction, and lead to good outcomes in some cases. However, there were also instances where patients died or remained dependent on hemodialysis. The text also compares the outcomes of patients who received TPE with those who received red blood cell exchange (RBCX) alone and found similar mortality rates and hospital length of stay. This document provides information on TPE procedures and outcomes for patients with multi-organ failure (MOF) and thrombotic microangiopathy (TMA) related to sickle cell disease. For MOF, TPE was performed after RBCX, with an average plasma volume exchanged of 3.0 liters. The most common TPE outcomes were clinical improvement, hospital length of stay, and in-hospital mortality. For TMA, TPE was used in combination with other treatments, [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
10. A rare case of acute cerebellitis due to enterovirus treated with therapeutic plasma exchange: Case report and review of the literature.
- Author
-
Akçay, Nihal, Topal, Neval, and Semerci, Seda Yılmaz
- Subjects
PLASMA exchange (Therapeutics) ,LITERATURE reviews ,POLYMERASE chain reaction ,CHILD patients ,CLINICAL deterioration - Abstract
Background: Acute cerebellitis is a rare complication of pediatric infections. There are many reports that viral infections lead to neurological manifestations, including acute cerebellitis. Methods: A retrospective chart review was conducted for pediatric patients diagnosed with enterovirus cerebellitis between 2000 and 2024. The methods involved reviewing clinical and radiological records and assessing the treatment methods. Results: Case Report: We present the case of a 4‐year‐old immunocompetent child who initially presented with acute encephalopathy followed by truncal ataxia, and eventually received a diagnosis of postinfectious cerebellitis. Enterovirus real‐time polymerase chain reaction were positive in the nasopharyngeal swab. Therapeutic plasma exchange (TPE) was started due to neurological deterioration despite IVIG treatment. She improved significantly with TPE, and methylprednisolone treatment and was discharged in good health status. The patient is being followed up as neurologically normal. Conclusion: Acute cerebellitis associated with enterovirus is a rare pediatric disorder. Early diagnosis and treatment with TPE in this severe case is thought to be preventive for the potentially fatal complications. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Therapeutic role of plasma exchange in the management of stiff person syndrome: experience from a tertiary care centre
- Author
-
Vijay Kumawat, Parmatma Prasad Tripathi, Netravathi M, Anita Mahadevan, and Anchan Vidyashree Vittal
- Subjects
Stiff person syndrome ,Therapeutic plasma exchange ,Anti-GAD65 antibodies ,Modified Rankin score ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Introduction: The stiff person syndrome (SPS) is a rare and disabling neurological disorder characterized by muscle stiffness, painful spasms and rigidity involving the proximal and axial limb muscles, with an estimated incidence of 1 case per million per year. The first line of treatment for symptomatic management includes gamma-aminobutyric acid (GABA)ergic agonists, benzodiazepines and baclofen. The therapeutic plasma exchange (TPE), alone or as an adjuvant to other forms of immunomodulation, has been used as a therapeutic option, particularly in refractory cases. Methods: An observational study was performed to review SPS patient symptoms, comorbidities, electromyography (EMG) studies and treatment, identifying autoantibodies, therapeutic plasma exchange (TPE) procedural details and clinical response. Main results: Five patients (4 male and one female) were treated with TPE during the study period as adjuvant therapy. The average age was 47 years (range 34 - 61 years), and anti-glutamic acid decarboxylase 65-kilodalton isoform (anti-GAD65) antibodies were positive in 80 % (4/5) of the patient population. All patients received immunosuppressive drugs along with TPE. Four patients received TPE during the first admission and one received it during the third hospital admission. All patients showed good improvement immediately after TPE, but it was not a sustainable effect. Conclusion: TPE may be helpful as adjuvant therapy for SPS patients to provide relief from clinical symptoms
- Published
- 2024
- Full Text
- View/download PDF
12. RescuE pLAsma eXchange in Severe COVID-19 (RELAX)
- Author
-
Christian Nusshag, MD, Attending, Department of Nephrology
- Published
- 2023
13. Impact of therapeutic plasma exchange intervention timing and liver injury periodization on the prognosis of patients with exertional heat stroke
- Author
-
Zongzhong HE, Min WANG, Yuan ZHUANG, Jie LIN, Leiying ZHANG, Liyang ZOU, Lingling LI, Chunya MA, Xiaomin LIU, Xiang QUAN, Ying JIANG, Mou ZHOU, Hongjun KANG, and Yang YU
- Subjects
exertional heat stroke(ehs) ,liver injury ,therapeutic plasma exchange ,Diseases of the blood and blood-forming organs ,RC633-647.5 ,Medicine - Abstract
Objective To explore the prognostic impact and clinical application value of therapeutic plasma exchange(TPE) intervention timing and liver injury periodization in patients with exertional heat stroke(EHS). Methods Data of 127 EHS patients from the First Medical Center of the General Hospital of the People′s Liberation Army from January 2011 to December 2023 were collected, then divided into the death group and the survival group based on therapeutic outcomes and into 5 stages according to the dynamic changes of ALT, AST, TBIL and DBIL. According to propensity score matching analysis, 11 patients in the survival group and 12 patients in the death group were included in the statistical analysis, and 20 of them were treated with TPE. The changes in indicators and clinical outcomes before and after TPE were observed, in order to evaluate the impact of intervention timing on prognosis. Results Among the 23 patients, 14 had no liver injury or could progress to the repair phase, resulting in 3 deaths(with the mortality rate of 21.43%), while 9 patients failed to progress to the repair phase, resulting in 9 deaths(with the mortality rate of 100%), with significant differences(P
- Published
- 2024
- Full Text
- View/download PDF
14. Bloodstream infections among patients receiving therapeutic plasma exchanges in the intensive care unit: a 10 year multicentric study
- Author
-
Sofiane Fodil, Tomas Urbina, Swann Bredin, Julien Mayaux, Antoine Lafarge, Louaï Missri, Eric Maury, Alexandre Demoule, Frederic Pene, Eric Mariotte, and Hafid Ait-Oufella
- Subjects
Therapeutic plasma exchange ,Intensive care unit ,Critical care ,Bloodstream infections ,Intra-vascular catheter infection ,Health-care acquired infections ,Medical emergencies. Critical care. Intensive care. First aid ,RC86-88.9 - Abstract
Abstract Background Therapeutic plasma exchanges (TPE), which affect the humoral response, are often performed in combination with immunosuppressive drugs. For this reason, TPE may be associated with an increased susceptibility to infections. We aimed to describe blood stream infection (BSI) incidence in ICU patients treated with TPE and to identify associated risk factors. Methods We retrospectively included patients that had received at least one session of TPE in the ICU of one of the 4 participating centers (all in Paris, France) between January 1st 2010 and December 31th 2019. Patients presenting with a BSI during ICU stay were compared to patients without such an infection. Risk factors for BSI were identified by a multivariate logistic regression model. Results Over 10 years in the 4 ICUs, 387 patients were included, with a median of 5 [2–7] TPE sessions per patient. Most frequent indications for TPE were thrombotic microangiopathy (47%), central nervous system inflammatory disorders (11%), hyperviscosity syndrome (11%) and ANCA associated vasculitis (8.5%). Thirty-one patients (8%) presented with a BSI during their ICU stay, a median of 7 [3–11] days after start of TPE. In a multivariate logistic regression model, diabetes (OR 3.32 [1.21–8.32]) and total number of TPE sessions (OR 1.14 [1.08–1.20]) were independent risk factors for BSI. There was no difference between TPE catheter infection related BSI (n = 11 (35%)) and other sources of BSI (n = 20 (65%)) regarding catheter insertion site (p = 0.458) or rate of TPE catheter related deep vein thrombosis (p = 0.601). ICU course was severe in patients presenting with BSI when compared to patients without BSI, with higher need for mechanical ventilation (45% vs 18%, p = 0.001), renal replacement therapy (42% vs 20%, p = 0.011), vasopressors (32% vs 12%, p = 0.004) and a higher mortality (19% vs 5%, p = 0.010). Conclusion Blood stream infections are frequent in patients receiving TPE in the ICU, and are associated with a severe ICU course. Vigilant monitoring is crucial particularly for patients receiving a high number of TPE sessions.
- Published
- 2024
- Full Text
- View/download PDF
15. Role of plasma exchange in a post-partum case of severe thrombotic thrombocytopenic purpura with acute kidney injury
- Author
-
Jyoti Bharti, Tulika Chandra, Archana Solanki, Ashutosh Singh, D. Himanshu Reddy, and Mallika Agarwal
- Subjects
acute kidney injury ,fresh frozen plasma ,post-partum thrombotic thrombocytopenic purpura ,therapeutic plasma exchange ,ttp ,Medicine - Abstract
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease present with the classic pentad of microangiopathic hemolytic anemia (MAHA), fever, neurologic changes, thrombocytopenia, and renal dysfunction. In a diagnostic dilemma, therapeutic plasma exchange (TPE) is a choice of life-saving intervention. In this, we assess the efficacy of TPE in a suspected case of post-partum TTP. A 27 years old female was admitted in an emergency on day 8 after a lower segment cesarian section (LSCS) with unresponsive behavior for 3 days and with TTP. She was normal 32 days back with her second, 7-month pregnancy. Ultrasonography (USG) showed an umbilical cord around the neck of the baby. On the fifth post-operative day, she was shifted to emergency with fever, generalized anasarca, gastrointestinal tract (GI) bleeding, low platelet count, and low Hb, with a poor Glasgow coma scale (GCS) of 6. On the bases of serum urea and serum creatinine, she presented acute kidney injury with encephalopathy. At emergency, she was unresponsive to mechanical ventilation and supportive treatment; hence, therapeutic plasma exchange was performed. After eight TPE cycles, the patient presented with an improved hematological and renal profile with good GCS. TPE is helpful and life-saving for suspected TTP patients with AKI.
- Published
- 2024
- Full Text
- View/download PDF
16. Effectiveness of Therapeutic Plasma Exchange in Autoimmune Neurological Diseases in a Tertiary Care Hospital of South India
- Author
-
Murali Krishna Bogi, Kandukuri Mahesh Kumar, Sudhir Kumar Vujhini, and Shanthi Bonagiri
- Subjects
autoantibodies ,autoimmune disease ,guillain–barre syndrome ,myasthenia gravis ,therapeutic plasma exchange ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Background and Objectives: Therapeutic plasma exchange (TPE) is commonly used as a treatment of certain autoimmune neurological diseases, and its main target is to remove pathogenical toxins or autoantibodies. Removed plasma with toxins and autoantibodies is replaced by crystalloids, colloids, and/or normal saline. It is more effective and cost-effective than immunoglobulins. The aim of this study was to know the effectiveness of TPE in autoimmune neurological diseases. Methods: This is a prospective study involving 376 autoimmune neurological cases, and the duration of this study was 5 years. All autoimmune neurological patients irrespective of age with complaints of weakness in limbs, respiratory distress, and acute myasthenia gravis (MG) crisis cases were included in the study. The Modified Rankin Score and MG Composite Score were used to analyze the severity of the disease, and the number of TPE procedures or cycles was planned. Results: The total number of cases included was 376 (322 newly registered cases and 54 old and relapse cases), and the total number of TPE procedures done was 1491 between the years 2017 and 2021. Male patients were 138 and female patients 238. The most number of cases were of MG, followed by Guillain–Barre syndrome. The mean number of TPE procedures done was 6.1 cycles in myasthenia crisis patients. There was a significant improvement in the patients after the treatment. The Modified Rankin Score and MG Composite Score were 1/6 and 3/50, respectively (P = 0.0321 and P = 0.0298, respectively) after completion of the TPE. Conclusion: TPE is the most effective method in cases of neurological autoimmune diseases. Most of the cases show improvement immediately after the first cycle, and more than half of the cases will be able to walk or do their routine activities after 2 or 3 cycles. It is a safe and cost-effective treatment modality with minimal side effects or complications.
- Published
- 2024
- Full Text
- View/download PDF
17. A Case Report on the Successful Management of Catastrophic Antiphospholipid Syndrome: Multidisciplinary Approach
- Author
-
Pragya Silwal, Aseem Kumar Tiwari, Geet Aggarwal, Chitra Mehta, and Yatin Mehta
- Subjects
antiphospholipid antibody ,catastrophic antiphospholipid syndrome ,plasma exchange ,therapeutic plasma exchange ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Catastrophic antiphospholipid syndrome (CAPS) is a multi-organ systemic thrombotic condition precipitated due to various secondary conditions such as infection, surgery, and estrogen use. The subsequent formation of various autoantibodies and various organ involvement such as the brain, heart, and kidneys cause rapid progression of the disease. The acute features of thrombosis and the predominant involvement of kidneys and the brain make the differentiation of this condition with other thrombotic microangiopathies difficult. However, early suspicion of CAPS with prompt management is key to favorable prognosis in such patients. Multidisciplinary approach to diagnosis and medical management plays an important role in the successful outcome of CAPS patients. The three pillars of management are therapeutic plasma exchange (TPE), steroids, and anticoagulants. TPE plays a major role in eliminating incriminating antibodies, cytokines, tumor necrosis factor, and complement. We present a case of 34-year-old female with definite CAPS, managed successfully with the triple regimen comprising a total of seven TPE sessions, pulse therapy with steroids, and anticoagulants.
- Published
- 2024
- Full Text
- View/download PDF
18. Bloodstream infections among patients receiving therapeutic plasma exchanges in the intensive care unit: a 10 year multicentric study.
- Author
-
Fodil, Sofiane, Urbina, Tomas, Bredin, Swann, Mayaux, Julien, Lafarge, Antoine, Missri, Louaï, Maury, Eric, Demoule, Alexandre, Pene, Frederic, Mariotte, Eric, and Ait-Oufella, Hafid
- Subjects
- *
RISK assessment , *VASCULITIS , *CRITICALLY ill , *PATIENTS , *THERAPEUTICS , *RENAL replacement therapy , *BLOODBORNE infections , *CATHETER-related infections , *MULTIPLE regression analysis , *ANTINEUTROPHIL cytoplasmic antibodies , *VENOUS thrombosis , *DESCRIPTIVE statistics , *RETROSPECTIVE studies , *ODDS ratio , *LONGITUDINAL method , *INTENSIVE care units , *RESEARCH , *ARTIFICIAL respiration , *VASOCONSTRICTORS , *PLASMA exchange (Therapeutics) , *COMORBIDITY , *DISEASE risk factors - Abstract
Background: Therapeutic plasma exchanges (TPE), which affect the humoral response, are often performed in combination with immunosuppressive drugs. For this reason, TPE may be associated with an increased susceptibility to infections. We aimed to describe blood stream infection (BSI) incidence in ICU patients treated with TPE and to identify associated risk factors. Methods: We retrospectively included patients that had received at least one session of TPE in the ICU of one of the 4 participating centers (all in Paris, France) between January 1st 2010 and December 31th 2019. Patients presenting with a BSI during ICU stay were compared to patients without such an infection. Risk factors for BSI were identified by a multivariate logistic regression model. Results: Over 10 years in the 4 ICUs, 387 patients were included, with a median of 5 [2–7] TPE sessions per patient. Most frequent indications for TPE were thrombotic microangiopathy (47%), central nervous system inflammatory disorders (11%), hyperviscosity syndrome (11%) and ANCA associated vasculitis (8.5%). Thirty-one patients (8%) presented with a BSI during their ICU stay, a median of 7 [3–11] days after start of TPE. In a multivariate logistic regression model, diabetes (OR 3.32 [1.21–8.32]) and total number of TPE sessions (OR 1.14 [1.08–1.20]) were independent risk factors for BSI. There was no difference between TPE catheter infection related BSI (n = 11 (35%)) and other sources of BSI (n = 20 (65%)) regarding catheter insertion site (p = 0.458) or rate of TPE catheter related deep vein thrombosis (p = 0.601). ICU course was severe in patients presenting with BSI when compared to patients without BSI, with higher need for mechanical ventilation (45% vs 18%, p = 0.001), renal replacement therapy (42% vs 20%, p = 0.011), vasopressors (32% vs 12%, p = 0.004) and a higher mortality (19% vs 5%, p = 0.010). Conclusion: Blood stream infections are frequent in patients receiving TPE in the ICU, and are associated with a severe ICU course. Vigilant monitoring is crucial particularly for patients receiving a high number of TPE sessions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy.
- Author
-
Dima, Danai, Goel, Utkarsh, Sannareddy, Aishwarya, Ibeh, Nnaemeka, Ullah, Fauzia, Afrough, Aimaz, Mazzoni, Sandra, Mehdi, Ali, Rudoni, Joslyn, Raza, Shahzad, De Simone, Nicole, Williams, Louis, Khan, Adeel, Rashid, Aliya, Rice, Mikhaila, Ricci, Kristin, Samaras, Christy, Valent, Jason, Anderson, Larry D., and Anwer, Faiz
- Subjects
PLASMA exchange (Therapeutics) ,TREATMENT effectiveness ,MULTIPLE myeloma ,IMMUNOGLOBULIN light chains ,KIDNEY diseases - Abstract
Current treatment guidelines of myeloma cast nephropathy (MCN) recommend the institution of plasma cell‐directed therapy and consideration of therapeutic plasma exchange (TPE), with the goal of rapid reduction of the serum free light chain (sFLC). However, the role of TPE continues to remain a subject of debate. The goal of this retrospective bi‐institutional study was to evaluate the clinical outcomes of TPE in combination with systemic therapy. Eighty patients were included in this analysis, of whom 72.5% had ≥50% drop in their initial involved sFLC. At 3 months from TPE initiation, the overall hematologic response rate (ORR) was 67.5% with a very good partial response or better (≥VGPR) rate of 40%. At 6 months, ORR was 57.5%, with ≥VGPR rate of 49%. The renal response rate at 3 and 6 months was 47.5% and 43.75%, respectively; the overall renal response rate was 48.75%. On multivariable analysis, every one unit increase in baseline creatinine (odds ratio [OR] 0.76, p = 0.006), and achievement of ≥VGPR (OR 21.7 p < 0.0001) were significantly associated with renal response. Also, a ≥50% drop in sFLC was favorably associated with renal response (OR 3.39, p = 0.09). With a median follow‐up of 36.4 months, the median overall survival (OS) was 11 months. On multivariable analysis, achievement of renal response (hazard ratio [HR] 0.3, p < 0.0001) and newly diagnosed disease (NDMM; HR 0.43, p = 0.0055) were associated with improved OS. Among NDMM patients, those treated with daratumumab‐based regimens had a trend for better OS (p = 0.15), compared to other regimens, but the difference was not significant. At the end of follow‐up, an estimated 40.4% of patients who were on dialysis were able to become dialysis independent. In conclusion, our study highlights the poor survival of patients with MCN. Achievement of early renal response is crucial for prolonged OS, with daratumumab‐based therapies showing promise. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Role of plasma exchange in a post‑partum case of severe thrombotic thrombocytopenic purpura with acute kidney injury.
- Author
-
Bharti, Jyoti, Chandra, Tulika, Solanki, Archana, Singh, Ashutosh, Reddy, D. Himanshu, and Agarwal, Mallika
- Subjects
- *
PLASMA exchange (Therapeutics) , *ACUTE kidney failure , *GLASGOW Coma Scale , *PLASMA products , *KIDNEY diseases , *THROMBOTIC thrombocytopenic purpura - Abstract
Thrombotic thrombocytopenic purpura (TTP) is a life‑threatening disease present with the classic pentad of microangiopathic hemolytic anemia (MAHA), fever, neurologic changes, thrombocytopenia, and renal dysfunction. In a diagnostic dilemma, therapeutic plasma exchange (TPE) is a choice of life‑saving intervention. In this, we assess the efficacy of TPE in a suspected case of post‑partum TTP. A 27 years old female was admitted in an emergency on day 8 after a lower segment cesarian section (LSCS) with unresponsive behavior for 3 days and with TTP. She was normal 32 days back with her second, 7‑month pregnancy. Ultrasonography (USG) showed an umbilical cord around the neck of the baby. On the fifth post‑operative day, she was shifted to emergency with fever, generalized anasarca, gastrointestinal tract (GI) bleeding, low platelet count, and low Hb, with a poor Glasgow coma scale (GCS) of 6. On the bases of serum urea and serum creatinine, she presented acute kidney injury with encephalopathy. At emergency, she was unresponsive to mechanical ventilation and supportive treatment; hence, therapeutic plasma exchange was performed. After eight TPE cycles, the patient presented with an improved hematological and renal profile with good GCS. TPE is helpful and life‑saving for suspected TTP patients with AKI. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Blood-based therapies to combat neurodegenerative diseases.
- Author
-
Lee, Jia Yee, Lim, Mervyn Chen Xi, Koh, Rhun Yian, Tsen, Min Tze, and Chye, Soi Moi
- Subjects
- *
NEURODEGENERATION , *OLDER people , *ALZHEIMER'S disease , *DEGENERATION (Pathology) , *TREATMENT effectiveness , *APOLIPOPROTEIN E4 - Abstract
Neurodegeneration, known as the progressive loss of neurons in terms of their structure and function, is the principal pathophysiological change found in the majority of brain-related disorders. Ageing has been considered the most well-established risk factor in most common neurodegenerative diseases, such as Parkinson's disease (PD) and Alzheimer's disease (AD). There is currently no effective treatment or cure for these diseases; the approved therapeutic options to date are only for palliative care. Ageing and neurodegenerative diseases are closely intertwined; reversing the aspects of brain ageing could theoretically mitigate age-related neurodegeneration. Ever since the regenerative properties of young blood on aged tissues came to light, substantial efforts have been focused on identifying and characterizing the circulating factors in the young and old systemic milieu that may attenuate or accentuate brain ageing and neurodegeneration. Later studies discovered the superiority of old plasma dilution in tissue rejuvenation, which is achieved through a molecular reset of the systemic proteome. These findings supported the use of therapeutic blood exchange for the treatment of degenerative diseases in older individuals. The first objective of this article is to explore the rejuvenating properties of blood-based therapies in the ageing brains and their therapeutic effects on AD. Then, we also look into the clinical applications, various limitations, and challenges associated with blood-based therapies for AD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Therapeutic plasma exchange in paediatric nephrology in Ireland.
- Author
-
Wildes, Dermot M., Devlin, Conor, Costigan, Caoimhe Suzanne, Raftery, Tara, Hensey, Conor, Waldron, Mary, Dolan, Niamh, Riordan, Michael, Sweeney, Clodagh, Stack, Maria, Cotter, Melanie, Lynch, Bryan, Gorman, Kathleen Mary, and Awan, Atif
- Abstract
Background: Therapeutic plasma exchange (TPE) is utilised in the management of a limited number of paediatric renal conditions. Despite its widespread acceptance and advancements in the practice of apheresis, there remains a paucity of data pertaining to paediatrics. We present a large retrospective review of our cohort of paediatric patients undergoing TPE for renal indications, outlining their outcomes and complications. Methods: A retrospective chart review was conducted for all patients (under 16 years) undergoing TPE for renal conditions between January 2002 and June 2019 in Ireland. Demographic and clinical data were extracted, with patients anonymised and stratified according to their pathology. Results: A total of 58 patients were identified. A total of 1137 exchanges were performed using heparin sodium anticoagulation. The median age was 35.5 months (IQR 18–110 months). The leading indication was neurological involvement in Shiga toxin–producing Escherichia coli haemolytic uraemic syndrome (STEC-HUS) (n = 29). Complications (minor or major) occurred in 65.5% (n = 38) of patients, with most experiencing minor complications 58.6% (n = 34). Asymptomatic hypocalcaemia was the most common complication in 43.1% (n = 25). Conclusions: Our experience of TPE, spanning 1137 exchanges, proved a safe, well-tolerated therapy. Most complications were minor, and with therapy conducted in specialised centres, there are very low levels of adverse events. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Therapeutic plasma exchange for refractory Kawasaki disease in children weighing less than 10 kg.
- Author
-
Sawada, Mariko, Ogino, Kayo, Hayashi, Tomohiro, and Waki, Kenji
- Subjects
PLASMA exchange (Therapeutics) ,MUCOCUTANEOUS lymph node syndrome ,LEUCOCYTES ,CORONARY artery disease ,REFRACTORY materials - Abstract
Introduction: Therapeutic plasma exchange (TPE) is used for treating refractory Kawasaki disease (KD); however, there are few reports on its use in small children. Methods: Nine children with refractory KD who underwent TPE between January 2010 and December 2022 were retrospectively investigated. Data on patient demographics, inflammatory markers, coronary artery lesions (CALs), TPE settings and complications, and outcomes were examined. Results: A total of 37 TPE sessions were performed on nine patients, with 3–6 sessions per patient. The median body weight was 8.9 kg. C‐reactive protein, white blood cell (WBC), and interleukin‐6 levels significantly decreased (p < 0.05). Of the 33 coronary arteries with CALs before TPE, 44% and 3% had CALs at 1 month and 1 year after TPE, respectively. Minor complications, such as mild hypocalcemia and naturally recovering coagulopathy, occurred without serious complications. Conclusions: TPE for refractory KD may be safe and effective in preventing CALs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. 科学的根拠に基づいたアルブミン製剤の使用ガイドライン(改訂第3 版.
- Author
-
野﨑 昭人皿, 安村 敏皿, 佐藤 智彦, 田中 朝志, 米村 雄士, 口 松﨑 浩史, 河野 武弘皿, 志村 勇司, 牧野 茂義, and 松本 雅則
- Subjects
- *
PLASMA exchange (Therapeutics) , *CARDIAC surgery , *ALBUMINS , *ASCITES - Published
- 2024
25. Evaluation of the results of the patients who underwent plasmapheresis in the pediatric intensive care unit.
- Author
-
TALAY, Mehmet Nur, ORHAN, Özhan, KANĞIN, Murat, TURANLI, Eşe Eda, and ÖZBEK, Mehmet Nuri
- Subjects
- *
PEDIATRIC intensive care , *INTENSIVE care units , *HEMOLYTIC-uremic syndrome , *PLASMA exchange (Therapeutics) , *PLASMAPHERESIS , *BLOOD plasma - Abstract
Background/aim: Therapeutic plasma exchange (TPE) is an extracorporeal treatment method that removes large molecular weight substances from plasma. In our study, we aimed to retrospectively examine the indications and procedural methods of the patients who had undergone TPE, and the complications that occurred during the procedure. Materials and methods: Forty-one patients who were monitored in thePICU of Gazi Yaşargil Training and Research Hospital and had indications for TPE between 2017 and 2021 were included in the study. Laboratory parameters were checked before and after the TPE procedure. In addition to these, patients’ diagnosis, weight, type of procedure and type of device, where the procedure was performed, duration of the procedure, amount of blood and plasma processed, complications, number of procedures, and death during the procedure or independent of the procedure were evaluated. Results: The median age was 93.0 (14.0–167.0) months. Hemolytic uremic syndrome (HUS) was the most common TPE indication with nine patients. The most common complication related to TPE was fever (11 patients), while no complication was observed in 18 patients. When laboratory results were evaluated according to American Society for Apheresis (ASFA) categories, a significant improvement was observed in the values of platelet, AST, ALT, LDH, urea, and creatinine in ASFA1 after TPE. No significant improvement was observed in ASFA2 (p > 0.05). In ASFA3, a significant improvement was observed in INR, AST, ALT, LDH, total bilirubin, creatinine, pH, and lactate values after TPE (p < 0.05). Five patients died from ASFA1, one from ASFA2, and three patients from ASFA3. Conclusion: Since significant adjustments are observed in clinical and laboratory values in sepsis-MOF, which is in the ASFA3 category, we believe that it should be evaluated in the ASFA2 or ASFA1 category in the early treatment of these diseases. In addition, we think that MIS-C cases, which have not been in any category according to ASFA, should be included in the ASFA2 or ASFA3 category, considering our TPE results. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Trends in category and grade for therapeutic plasma exchange in the latest guideline on therapeutic apheresis by the American Society for Apheresis: Hurdles in pursuing evidence‐based medicine.
- Author
-
Kim, Han Joo, Chung, Yousun, Kim, Hyungsuk, Hwang, Sang‐Hyun, Oh, Heung‐Bum, and Ko, Dae‐Hyun
- Subjects
- *
PLASMA exchange (Therapeutics) , *EVIDENCE-based medicine , *HEMAPHERESIS , *EVIDENCE gaps , *PLASMA focus - Abstract
Background and Objectives: The Writing Committee of American Society for Apheresis released the ninth edition of guidelines for therapeutic apheresis in 2023. Categories have been a part of the guidelines since the first edition, and the grading system was introduced in the fifth edition, with updates in every new edition. In this study, we investigated the category and grade change trends through the latest five editions, focusing on therapeutic plasma exchange, to suggest future directions as part of evidence‐based medicine. Materials and Methods: Categories and grades for therapeutic plasma exchange (TPE) were collected and analysed from the fifth through ninth editions. We aligned classification changes to the ninth edition's clinical context and compared its categories and grades with those introduced in the guideline. Results: Among 166 total indications in the ninth edition, 118 included TPE procedure, either as a sole treatment or as one of the therapeutic apheresis techniques. The total number of indications changed, but Category III remained predominant throughout the editions. Similarly, Grade 2C consistently emerged as the most prevalent grade. Notably, 24 cases had grade changes. Of the 16 cases with evidence quality changes, the quality weakened in six and improved in 10. Evidence levels were not improved throughout the study period for 102 clinical conditions. Conclusion: To address gaps in evidence quality, international collaboration is imperative to establish comprehensive large‐scale studies or randomized controlled trials. This will refine the use of therapeutic apheresis, including TPE, to foster evidence‐based advancements in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Comparative metabolome analysis reveals higher potential of haemoperfusion adsorption in providing favourable outcome in ACLF patients.
- Author
-
Yadav, Manisha, Maiwal, Rakhi, Kumar BR, Vinay, Tripathi, Gaurav, Sharma, Neha, Sharma, Nupur, Bindal, Vasundhra, Mathew, Babu, Pandey, Sushmita, Singh, Satender Pal, Tevathia, Harsh Vardhan, Maras, Jaswinder Singh, and Sarin, Shiv Kumar
- Subjects
- *
PLASMA exchange (Therapeutics) , *BILE acids , *LIVER regeneration , *ARACHIDONIC acid , *MICROBIAL metabolism - Abstract
Background and Aims: Acute‐on‐chronic liver failure (ACLF) is a serious illness associated with altered metabolome, organ failure and high mortality. Need for therapies to improve the metabolic milieu and support liver regeneration are urgently needed. Methods: We investigated the ability of haemoperfusion adsorption (HA) and therapeutic plasma exchange (TPE) in improving the metabolic profile and survival in ACLF patients. Altogether, 45 ACLF patients were randomized into three groups: standard medical therapy (SMT), HA and TPE groups. Plasma metabolomics was performed at baseline, post‐HA and TPE sessions on days 7 and 14 using high‐resolution mass spectrometry. Results: The baseline clinical/metabolic profiles of study groups were comparable. We identified 477 metabolites. Of these, 256 metabolites were significantly altered post 7 days of HA therapy (p <.05, FC > 1.5) and significantly reduced metabolites linked to purine (12 metabolites), tryptophan (7 metabolites), primary bile acid (6 metabolites) and arginine‐proline metabolism (6 metabolites) and microbial metabolism respectively (p <.05). Metabolites linked to taurine‐hypotaurine and histidine metabolism were reduced and temporal increase in metabolites linked to phenylalanine and tryptophan metabolism was observed post‐TPE therapy (p <.05). Finally, weighted metabolite correlation network analysis (WMCNA) along with inter/intragroup analysis confirmed significant reduction in inflammatory (tryptophan, arachidonic acid and bile acid metabolism) and secondary energy metabolic pathways post‐HA therapy compared to TPE and SMT (p <.05). Higher baseline plasma level of 11‐deoxycorticosterone (C03205; AUROC > 0.90, HR > 3.2) correlated with severity (r2 > 0.5, p <.05) and mortality (log‐rank‐p <.05). Notably, 51 of the 64 metabolite signatures (ACLF non‐survivor) were reversed post‐HA treatment compared to TPE and SMT(p <.05). Conclusion: HA more potentially (~80%) improves plasma milieu compared to TPE and SMT. High baseline plasma 11‐deoxycorticosterone level correlates with early mortality in ACLF patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. The Use of Apheresis in Personalized Cell-Mediated Treatment of Prostate Cancer
- Author
-
Balint, Bela, Pavlovic, Mirjana, Todorovic, Milena, Kocic, Gordana, editor, Hadzi-Djokic, Jovan, editor, and Simic, Tatjana, editor
- Published
- 2024
- Full Text
- View/download PDF
29. Plasmapherese bei Sepsis
- Author
-
Stahl, Klaus, Bode, Christian, and David, Sascha
- Published
- 2024
- Full Text
- View/download PDF
30. Initial US tertiary health care system experience using caplacizumab in patients with immune thrombotic thrombocytopenic purpura
- Author
-
Jones, Jennifer M., Kaplan, Alesia, Chibisov, Irina, Then, Janine, Novelli, Enrico M., and Kiss, Joseph E.
- Published
- 2024
- Full Text
- View/download PDF
31. Apheresis Indications in the Perioperative Setting
- Author
-
Shih, Pauline A., Fontaine, Magali J., and Lokhandwala, Parvez M.
- Published
- 2024
- Full Text
- View/download PDF
32. Comparative efficacy of therapeutic plasma exchange and insulin in hypertriglyceridemia-induced acute pancreatitis
- Author
-
Thanh, Nguyen Huu, Nhi, Pham Yen, Huyen, Nguyen Thu, and Hai, Pham Dang
- Published
- 2024
- Full Text
- View/download PDF
33. Therapeutic plasma exchange decreases serum triglyceride level rapidly and reduces early recurrence rate but no advantages in improving outcomes for patients with hyperlipidemic acute pancreatitis: a retrospective propensity score matching analysis based on twenty year’s experience
- Author
-
Canbin Zheng, Yongping Zheng, and Zihui Zheng
- Subjects
Hyperlipidemic acute pancreatitis ,Therapeutic plasma exchange ,Propensity score matching ,Recurrence ,Local complications ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Abstract Background Hyperlipidaemic acute pancreatitis (HLAP) has become the most common cause of acute pancreatitis (AP) not due to gallstones or alcohol (Mosztbacher et al, Pancreatology 20:608-616, 2020; Yin et al, Pancreas 46:504-509, 2017). Therapeutic plasma exchange (TPE) has been reported to be effective in reducing serum TG levels which is important in management of HLAP (World J Clin Cases 9:5794-803, 2021). However, studies on TPE are mostly focusing on cases reports, TPE remains poorly evaluated till date and need to be compared with conservative therapy with a well-designed study. Methods A retrospectively cohort study on HLAP patients between January 2003 and July 2023 was conducted. Factors correlated with efficacy of TPE were included in a propensity model to balance the confounding factors and minimize selection bias. Patients with and without TPE were matched 1:2 based on the propensity score to generate the compared groups. Lipid profiles were detected on admission and consecutive 7 days. The triglyceride (TG) level decline rates, percentage of patients to reach the target TG levels, early recurrence rate, local complications and mortality were compared between groups. Results A total of 504 HLAP patients were identified. Since TPE was scarcely performed on patients with TG
- Published
- 2024
- Full Text
- View/download PDF
34. Role of therapeutic plasma exchange in management of hemolysis associated with extracorporeal membrane oxygenation in neonates with congenital diaphragmatic hernia: A case series
- Author
-
Nicole Cimbak, Farokh R. Demehri, Jill M. Zalieckas, and Belinda Hsi Dickie
- Subjects
Therapeutic plasma exchange ,Extracorporeal membrane oxygenation ,Case series ,Pediatrics ,RJ1-570 ,Surgery ,RD1-811 - Abstract
Introduction: Plasma free hemoglobin (PFH) is a product of intravascular hemolysis associated with certain disease states as well as the shearing effects of mechanical support devices, such as extracorporeal membrane oxygenation (ECMO). There are detrimental effects of intravascular hemolysis secondary to ECMO including severe hyperbilirubinemia, thrombus within the ECMO circuit causing inability to provide adequate support, and as a result, a need for ECMO circuit exchanges. Neonates can experience renal failure, kernicterus, and other significant morbidities as a result of hemolysis secondary to ECMO. Case series: We present three cases of neonates with a gestational age of 35–37 weeks who had a left-sided CDH and were cannulated to VA-ECMO on the first day of life using an 8 French arterial cannula and a 10 French venous cannula. Within the first 10 days of the ECMO run all patients developed markedly elevated PFH of (peaks of 465, >500 and > 500 mg/dL), and creatinine, and underwent therapeutic plasma exchange (TPE). TPE was done using frozen fresh plasma (FFP) replacement in line with the ECMO circuit. All patients showed a remarkable decrease in the PFH levels after the TPE treatment. The number of TPE rounds ranged from 1 to 6, depending on the evolution of the PFH levels. One patient developed hypocalcemia that resulted in decreased cardiac pulsatility during the first round of TPE that resolved with aggressive calcium repletion. The total duration of the ECMO runs ranged from 16 to 29 days. None of the patients required continuous renal replacement therapy. All patients were discharged home at ages ranging from 2 to 6 months. Conclusion: Mechanical cell hemolysis is a significant source of morbidity in neonatal patients on ECMO. This case series exemplifies a safe and impactful intervention to address hemolysis in a critically ill patient population.
- Published
- 2024
- Full Text
- View/download PDF
35. Resolution of Extensive Xanthomas Associated With Severe Hypertriglyceridemia via Modified Therapeutic Plasma Exchange.
- Author
-
Aljabri, Bandari, Saber, Wafa, Alzahrani, Saud, and Dada, Ashraf
- Subjects
- *
PLASMA exchange (Therapeutics) , *HYPERTRIGLYCERIDEMIA , *PLASMAPHERESIS - Abstract
Severe hypertriglyceridemia can be manifested by xanthomas. Therapeutic plasma exchange (TPE) is an invasive medical procedure that has been documented as a viable approach for severe hypertriglyceridemia when cases would be refractory to conventional therapies. TPE is mainly an optional therapeutic modality for cases of severe acute pancreatitis or preventing the recurrence of pancreatitis. Beyond this clinical application, data are scarce on TPE utilization in managing cutaneous lesions associated with hypertriglyceridemia. We present a case of severe hypertriglyceridemia accompanied by extensive xanthomas of various types and a history of recurrent pancreatitis. After conventional therapy failed, a modified plasmapheresis regimen was used and was able to achieve a fast and marked reduction in the patient's serum triglyceride levels with complete resolution of the extensive cutaneous lesions, providing him a newfound comfort he had not experienced in some time and suggesting the regimen potentially could be considered in the treatment of refractory severe hypertriglyceridemia with debilitating cutaneous complications. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Efficacy of therapeutic plasma exchange in a case of severe, generalised canine pemphigus foliaceus.
- Author
-
Edmonds, Kaitlyn Bello, Her, Jiwoong, Langston, Catherine, Jennings, Ryan, and Diaz, Sandra
- Subjects
- *
PLASMA exchange (Therapeutics) , *TREATMENT effectiveness , *PEMPHIGUS , *BODY surface area - Abstract
Successful treatment of pemphigus foliaceus (PF) often requires a multimodal therapeutic approach. The dog described herein underwent four therapeutic plasma exchange treatments for severe, refractory PF, resulting in a 50% reduction of lesional body surface area. This treatment option should be considered for the management of canine PF. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Retrospective review of patients with myasthenia gravis switched from plasma exchange therapy to efgartigimod treatment.
- Author
-
Mehrabyan, Anahit and Traub, Rebecca E.
- Abstract
Introduction/Aims: Therapeutic plasma exchange (TPE) is sometimes used as maintenance therapy for the treatment of myasthenia gravis (MG). Efgartigimod is a newly approved monoclonal antibody targeting the neonatal Fc receptor, effectively reducing immunoglobulin G levels in the treatment of MG. The aim of this study was to describe the clinical experience of switching patients from maintenance TPE treatment to efgartigimod infusions. Methods: A retrospective review of medical records was performed on patients previously treated with maintenance TPE for the diagnosis of MG and subsequently switched to efgartigimod infusions. Clinical characteristics and response to treatment switch were described. Results: Five of seven patients demonstrated improvement on Myasthenia Gravis Foundation of America‐post intervention status, one was unchanged and one was in pharmacological remission. This was reflected in pre‐ and postswitch MG activities of daily living and MG manual muscle testing scores. All patients have continued on efgartigimod therapy. The duration of treatment with efgartigimod at the time of this review ranged from 1 to 13 months. Recurrent uncomplicated infections were noted in two patients on efgartigimod therapy. Maintenance dosing regimens of efgartigimod varied based on clinical response to treatment and side effects. Discussion: In this series, efgartigimod appeared effective and well tolerated in patients switched from TPE. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Efficacy and Safety of Therapeutic Plasma Exchange in Children with Neuroimmunological Disorders: A Limited Unicentral Study.
- Author
-
NIKKHAH, Ali, NASEHI, Mohammad Mahdi, MOMTAZMANESH, Nader, ETEMAD, Kourosh, and HAJATNIA, Somayeh
- Subjects
TREATMENT of encephalitis ,MULTIPLE sclerosis treatment ,AUTOIMMUNE disease treatment ,TREATMENT of Guillain-Barre syndrome ,NEUROMYELITIS optica ,PATIENT safety ,POSTVACCINAL encephalitis ,TREATMENT effectiveness ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,GLASGOW Coma Scale ,NEUROLOGICAL disorders ,OPTIC neuritis ,MEDICAL records ,ACQUISITION of data ,RESEARCH methodology ,DATA analysis software ,PLASMA exchange (Therapeutics) ,CHILDREN - Abstract
Objectives Therapeutic plasma exchange (TPE) is a plasmapheresis procedure whose Safety data for pediatric neuro-immunological disorders (PNID) is confined. The present research documents TPE's safety and feasibility data in these conditions. Materials & Methods The current study involved six distinct groups of patients with PNID undergoing TPE: neuromyelitis optic spectrum disorder (NMOSD), autoimmune encephalitis (AIE), acute disseminated encephalomyelitis (ADEM), multiple sclerosis (MS), Guillain-Barre syndrome (GBS), and optic neuritis (ON). This study documented complications related to each TPE process. In addition, TPE's efficacy was studied in these patients. Results The present study recorded adverse effects in 18 patients with PNID that received 121 TPE cycles: five cycles (4.13%) in MS, three (2.48%) in AIE subgroup, one (0.82%) in ADEM, and two (1.65%) in GBS. No severe complications were observed among the patients. Conclusion Patients with PNID tolerated therapeutic plasma exchange, which was a safe process. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Single-center Experience of Therapeutic Plasma Exchange in Children with Neuroimmunological Disorders: Indications, Efficacy, and Safety.
- Author
-
Günay, Çağatay, Arslan, Gazi, Özsoy, Özlem, Uzan, Gamze Sarıkaya, Aykol, Duygu, Besci, Tolga, Kurul, Semra Hız, Aydın, Adem, and Yiş, Uluç
- Abstract
This article explores the use of therapeutic plasma exchange (TPE) as a treatment for neuroimmunological disorders in children. The study found that TPE was effective and well-tolerated, with a partial response observed in most cases. However, despite positive clinical response, a high rate of neurological sequelae was observed. The article emphasizes the need for further research on the efficacy and safety of TPE in pediatric patients with neurological disorders. It also discusses the use of TPE in specific conditions such as Guillain-Barré syndrome and acute disseminated encephalomyelitis, highlighting the need for more research in these areas as well. Overall, the article suggests that TPE is a promising treatment option but more studies are needed to establish standard therapeutic modalities for pediatric patients. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
40. Investigation of the Effect of Therapeutic Plasma Exchange for TAFRO Syndrome: A Pilot Study.
- Author
-
Sonoda, Kosuke, Komatsu, Masamichi, Ozawa, Yoko, Yamamoto, Hiroshi, and Kamijo, Yuji
- Subjects
PLASMA exchange (Therapeutics) ,PILOT projects ,C-reactive protein ,BLOOD pressure ,SYNDROMES - Abstract
TAFRO syndrome is a rare systemic inflammatory disorder with a fatal course. Nevertheless, a definitive treatment strategy has not yet been established. Anti-inflammatory therapies, including glucocorticoid treatment and immunosuppressants, have not been satisfactory. Therefore, new treatment options are needed for patients with TAFRO syndrome. The effectiveness of therapeutic plasma exchange (TPE) has mainly been reported in several case reports. In this case series study, we investigated the effect of TPE on TAFRO syndrome. We reviewed six consecutive cases with TAFRO syndrome treated at Shinshu University Hospital. All of them underwent TPE. A significant improvement in mean blood pressure, albumin, total bilirubin, and C-reactive protein was observed after TPE. Furthermore, early TPE treatment was suggested to have an impact on the prognosis. More intensive studies are needed to emphasize the overall conclusion obtained that TPE can be an effective/acceptable treatment option for TAFRO syndrome. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Therapeutic plasma exchange decreases serum triglyceride level rapidly and reduces early recurrence rate but no advantages in improving outcomes for patients with hyperlipidemic acute pancreatitis: a retrospective propensity score matching analysis based on twenty year's experience
- Author
-
Zheng, Canbin, Zheng, Yongping, and Zheng, Zihui
- Subjects
- *
PANCREATITIS treatment , *HYPERLIPIDEMIA treatment , *CONSERVATIVE treatment , *MATHEMATICAL variables , *HYPERLIPIDEMIA , *ACUTE diseases , *RESEARCH funding , *PROBABILITY theory , *LIPIDS , *RETROSPECTIVE studies , *PANCREATITIS , *LONGITUDINAL method , *RESEARCH bias , *TRIGLYCERIDES , *DISEASE relapse , *COMPARATIVE studies , *PLASMA exchange (Therapeutics) , *DISEASE complications - Abstract
Background: Hyperlipidaemic acute pancreatitis (HLAP) has become the most common cause of acute pancreatitis (AP) not due to gallstones or alcohol (Mosztbacher et al, Pancreatology 20:608-616, 2020; Yin et al, Pancreas 46:504-509, 2017). Therapeutic plasma exchange (TPE) has been reported to be effective in reducing serum TG levels which is important in management of HLAP (World J Clin Cases 9:5794-803, 2021). However, studies on TPE are mostly focusing on cases reports, TPE remains poorly evaluated till date and need to be compared with conservative therapy with a well-designed study. Methods: A retrospectively cohort study on HLAP patients between January 2003 and July 2023 was conducted. Factors correlated with efficacy of TPE were included in a propensity model to balance the confounding factors and minimize selection bias. Patients with and without TPE were matched 1:2 based on the propensity score to generate the compared groups. Lipid profiles were detected on admission and consecutive 7 days. The triglyceride (TG) level decline rates, percentage of patients to reach the target TG levels, early recurrence rate, local complications and mortality were compared between groups. Results: A total of 504 HLAP patients were identified. Since TPE was scarcely performed on patients with TG < 11.3 mmol/L, 152 patients with TG level 5.65 to 11.3 mmol/L were excluded while 352 with TG ≧11.3 mmol/L were enrolled. After excluding 25 cases with incomplete data or pregnancy, 327 patients, of whom 109 treated without TPE while 218 treated with TPE, were included in data analysis. One-to-two propensity-score matching generated 78 pairs, 194 patients with well-balanced baseline characteristics. Of 194 patients enrolled after matching done, 78 were treated without while 116 with TPE. In the matched cohort (n = 194), patients treated with TPE had a higher TG decline rate in 48 h than those without TPE (70.00% vs 54.00%, P = 0.001); the early recurrence rates were 8.96% vs 1.83%, p = 0.055. If only SAP patients were analyzed, the early recurrence rates were 14.81% vs 0.00% (p = 0.026) respectively. For patients with CT severity index (CTSI) rechecked within 14 days, early CTSI improment rate were 40.90% vs 31.91%. Local complications checked 6 months after discharge were 44.12% vs 38.30%. Mortality was 1.28% vs 1.72%. No differences were found in early stage CTSI improment rate (P =.589), local complications (P =.451) or motality between two groups. Conclusions: TPE reduces TG levels more quickly in 48 h compared with those with conservative treatment, but no difference in the consecutive days. TPE tends to reduce the early recurrence rate comparing with conventional therapy, but TPE has no advantages in improving CTSI in early stage, and no improvement for outcomes including local complications and mortalty. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Trombotik Trombositopenik Purpura Tanılı Hastaların Klinik, Laboratuvar ve Tedavi Sonuçlarının Değerlendirilmesi.
- Author
-
Meşeli, Selin, Teke, Hava Üsküdar, Andıç, Neslihan, and Gündüz, Eren
- Abstract
Copyright of Osmangazi Journal of Medicine / Osmangazi Tip Dergisi is the property of Eskisehir Osmangazi University and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
43. Relevance of histopathological findings for predictive scoring of short-term treatment response to plasma exchange in severe ANCA-associated renal vasculitides.
- Author
-
Hakroush, Samy, Korsten, Peter, Ströbel, Philipp, and Tampe, Björn
- Subjects
PLASMA exchange (Therapeutics) ,HISTOPATHOLOGY ,ANTINEUTROPHIL cytoplasmic antibodies ,VASCULITIS ,MULTIPLE regression analysis - Abstract
Introduction: Rapidly progressive glomerulonephritis (RPGN) is characterized by a rapid loss of kidney function, affecting both renal and overall patient survival. Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small vessel vasculitis affecting multiple organ systems including the kidney, and among most frequent causes of RPGN. We here aimed to validate a recently described scoring system for short-term treatment response to therapeutic plasma exchange (PLEX) in a well-characterized and independent cohort of severe renal AAV presenting with RPGN. Furthermore, we compared this scoring with established classification systems in renal AAV including histopathological findings. Methods: We here directly compare the scoring system with retrospective data about PLEX treatment in our own clinical practice and according to current recommendations in a cohort of 53 patients with severe AAV presenting with RPGN confirmed by kidney biopsy. Results: We here confirm that PLEX scoring is capable to identify patients at risk for short-term poor outcome in severe AAV presenting with RPGN (p<0.0001). Furthermore, multiple stepwise regression analysis revealed that the PLEX score with renal biopsy performed best to predict poor outcome in this patient population (p<0.0001). Conclusion: Our observations underscore the relevance of performing a kidney biopsy in this patient population that is often challenged in the setting of intensive care treatment, requirement of KRT with need for anticoagulation and bleeding risk. Therefore, validation of our observations and this recent scoring system for treatment response to PLEX in independent cohorts would be of great clinical relevance in the treatment of patients with severe AAV presenting with RPGN. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Independent risk factors for in-hospital outcome of myasthenic crisis: a prospective cohort study.
- Author
-
Wang, Yuan, Huan, Xiao, Zhu, Xinfang, Song, Jie, Yan, Chong, Yang, Lei, Xi, Caihua, Xu, Yafang, Xi, Jianying, Zhao, Chongbo, Xia, Rong, and Luo, Sushan
- Subjects
MYASTHENIA gravis ,INTRAVENOUS immunoglobulins ,MUSCLE weakness ,PLASMA exchange (Therapeutics) ,THYMOMA - Abstract
Background: Myasthenic crisis (MC) is a life-threatening condition for myasthenia gravis (MG). Therapeutic plasma exchange (TPE) and intravenous immunoglobulin (IVIg) efficaciously treat patients with MC. However, not every MC responds well to rescue therapies, and the determinants for outcome with the evidence from prospective cohorts are still lacking. Objectives: To explore the risk factors for in-hospital outcomes in patients with MC. Methods: Using a national neuromuscular center-based cohort of MG with prospective follow-ups from the crisis to the post-crisis phase, we finally included 90 MC episodes from 76 independent patients who received a standard regimen of rescue therapies. Results: The mean admission age was 52.89 ± 15.72 years. With a female predominance of 63.16% (48/76) and a high proportion of thymoma-associated MG (TMG) of 63.16% (48/76), the overall in-hospital mortality was 2.63% (2/76) and the average duration for mechanical ventilation (MV) use was 17.09 ± 13.36 days (0–53 days). In contrast to the patients with anti-acetylcholine receptor (AChR) antibodies, muscle-specific tyrosine kinase (MuSK)-associated MC exhibited a shorter MV support (5.20 ± 5.07 versus 17.40 ± 13.24 days, p = 0.023), length of intensive care units (ICU) stay (6.00 ± 4.64 versus 19.16 ± 17.54 days, p = 0.046), and hospital stay (16.00 ± 4.12 versus 34.43 ± 20.48 days, p = 0.011). Thymoma [odds ratio (OR): 0.200, 95% confidence interval (CI): 0.058–0.687, p = 0.011], partial pressure of carbon dioxide (PCO
2 ) in blood gas before MV (OR: 1.238, 95% CI: 1.015–1.510, p = 0.035), and pneumonia (OR: 0.204, 95% CI: 0.049–0.841, p = 0.028) were identified as independent risk factors for prolonged MV use. TMG patients with thymoma burden exhibited a notable longer MV use (22.08 ± 17.54 versus 8.88 ± 6.79 days, p = 0.001), a prolonged hospital stay (40.40 ± 26.13 versus 23.67 ± 13.83 days, p = 0.009) compared with non-TMG. Even with complete thymoma resection (R0), TMG exhibited an unfavorable outcome versus non-TMG. Conclusion: With timely rescue therapies and prospective follow-ups, the in-hospital outcome of MCs was substantially improved. Thymoma, PCO2 in blood gas before MV, and pneumonia were identified as independent risk factors for prolonged MV use. Plain Language Summary: Risk factors for in-hospital outcome of myasthenic crisis Myasthenic crisis (MC) is a life-threatening condition for myasthenia gravis (MG). Therapeutic plasma exchange (TPE) and intravenous immunoglobulin (IVIg) efficaciously treat patients with MC. However, not every MC responds well to rescue therapies, and the determinants for outcome with the evidence from prospective cohorts are still lacking. Using a national neuromuscular center-based cohort of MG with prospective follow-ups from the crisis to the post-crisis phase, we were able to include 90 MC episodes from 76 independent patients who received a standard regimen of rescue therapies. The mean admission age was 52.89±15.72 years. With a female predominance and a high proportion of thymoma-associated MG. The overall in-hospital mortality was 2.63% (2/76) and the average duration for MV use was 17.09±13.36 days (0-53 days). In contrast to the patients with anti-AChR antibodies, MuSK-associated MC exhibited a shorter MV support, length of ICU stay and hospital stay. Thymoma, PCO2 in blood gas before MV, and pneumonia were identified as independent risk factors for prolonged MV use. TMG patients with thymoma burden exhibited a notable longer MV use, a prolonged hospital stay compared with non-TMG. Even with complete thymoma resection (R0), TMG exhibited an unfavorable outcome versus non-TMG. With timely rescue therapies and prospective follow-ups, the in-hospital outcome of MCs was substantially improved. Thymoma, PCO2 in blood gas before MV, and pneumonia. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
45. Use of therapeutic plasma exchange to remove lipoprotein X in a patient with vanishing bile duct syndrome presenting with cholestasis, pseudohyponatremia, and hypercholesterolemia: A case report and review of literature.
- Author
-
Jung, Yujung, Nelson, Heather A., and Lin, David Ming‐Hung
- Subjects
INTRAHEPATIC bile ducts ,PLASMA exchange (Therapeutics) ,LITERATURE reviews ,BILE ducts ,HYPERCHOLESTEREMIA ,HODGKIN'S disease - Abstract
Introduction: Lipoprotein X (Lp‐X) is an abnormal lipoprotein found in multiple disease conditions, including liver dysfunction and cholestasis. High Lp‐X concentrations can interfere with some laboratory testing that may result in spurious results. The detection of Lp‐X can be challenging, and there is currently a lack of consensus regarding the management of Lp‐X other than treating the underlying disease. Case Presentation: A 42‐year‐old female with Hodgkin's lymphoma treated with dexamethasone, high dose cytarabine and cisplatin and vanishing bile duct syndrome confirmed by liver biopsy presented with cholestasis, pseudohyponatremia (sodium, 113 mmol/L; reference range 136–146 mmL/L; serum osmolality, 303 mOsm/kg), and hypercholesterolemia (> 2800 mg/dL, reference range < 200 mg/dL). Lp‐X was confirmed by lipoprotein electrophoresis (EP). Although she did not manifest any specific signs or symptoms, therapeutic plasma exchange (TPE) was initiated based on laboratory findings of extreme hypercholesterolemia, spuriously abnormal serum sodium, and HDL values, and the potential for short‐ and long‐term sequelae such as hyperviscosity syndrome, xanthoma, and neuropathy. During the hospitalization, she was treated with four 1.0 plasma volume TPE over 6 days using 5% albumin for replacement fluid. After the first TPE, total cholesterol (TC) decreased to 383 mg/dL and sodium was measured at 131 mmol/L. The patient was transitioned into outpatient maintenance TPE to eliminate the potential of Lp‐X reappearance while the underlying disease was treated. Serial follow‐up laboratory testing with lipoprotein EP showed the disappearance of Lp‐X after nine TPEs over a 10‐week period. Literature Review: There are seven and four case reports of Lp‐X treated with TPE and lipoprotein apheresis (LA), respectively. While all previous case reports showed a reduction in TC levels, none had monitored the disappearance of Lp‐X after completing a course of therapeutic apheresis. Conclusion: Clinicians should have a heightened suspicion for the presence of abnormal Lp‐X in patients with cholestasis, hypercholesterolemia, and pseudohyponatremia. Once Lp‐X is confirmed by lipoprotein EP, TPE should be initiated to reduce TC level and remove abnormal Lp‐X. Most LA techniques are not expected to be beneficial since Lp‐X lacks apolipoprotein B. Therefore, we suggest that inpatient course of TPE be performed every other day until serum sodium, TC and HDL levels become normalized. Outpatient maintenance TPE may also be considered to keep Lp‐X levels low while the underlying disease is treated. Serum sodium, TC, and HDL levels should be monitored while on maintenance TPE. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Therapeutic plasma exchange for mechanical red cell hemolysis: A case series.
- Author
-
Douglas, Chloe E., House, Taylor R., Yalon, Larissa, and Menon, Shina
- Subjects
PLASMA exchange (Therapeutics) ,HEART assist devices ,HEMOLYSIS & hemolysins ,CHILD patients ,PEDIATRIC therapy - Abstract
We present three cases of severely elevated plasma free hemoglobin (PFH) in pediatric patients on mechanical circulatory support devices at a tertiary pediatric care center. Due to severe levels of PFH in the setting of critical illness with the inability to pursue immediate mechanical device exchange, membrane filtration therapeutic plasma exchange (TPE) was performed, which resulted in a lowering of PFH levels. However, long‐term outcomes were heterogeneous across the cases. This case series reviews patient presentation, organ function before and after TPE, and the overall role of TPE as an effective treatment option to decrease severely elevated PFH levels. In doing so, we hope to add to what is known about the use of TPE for mechanical red cell hemolysis and provide guidance on its use in critically ill patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. The role of plasmapheresis in severe acute disseminated encephalomyelitis with clinical findings of transverse myelitis.
- Author
-
Fjellbirkeland, Olivia W., Szpirt, Wladimir M., and Børresen, Malene L.
- Subjects
POSTVACCINAL encephalitis ,TRANSVERSE myelitis ,PLASMAPHERESIS ,CENTRAL nervous system diseases ,INTENSIVE care units - Abstract
Introduction: Acute disseminated encephalomyelitis is a rare acute demyelinating disease of the central nervous system (CNS). The pathogenesis remains unclear but is suspected to be autoimmune. High doses of methylprednisolone (HDMP) are currently considered standard of treatment. Plasmapheresis (PE) is typically given in steroid refractory cases. There is currently limited evidence supporting its use in ADEM. Materials and Methods: We report a 16‐year‐old girl with ADEM who improved rapidly after initiating PE. Results: The patient presented with acute onset of multifocal CNS symptoms, including encephalopathy, requiring intensive care unit management. Despite HDMP administration, her clinical condition continued to deteriorate. PE was therefore initiated on the same day as HDMP. Her clinical condition improved significantly following the first session. She was extubated and discharged from the intensive care unit the following day. Conclusion: HDMP combined with PE may be an effective first‐line treatment in patients with fulminant ADEM. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Rapidly progressive seronegative immune-mediated neuropathies responded to 'Remove and suppress' therapy with plasma exchange and B-cell suppression therapy
- Author
-
Stefanie Kar Yan Hung, Daniel Tze Wei Yeap, Thanusha Karunakaran, Dhayalen Krishnan, Sow Kuan Tee, and Fu Liong Hiew
- Subjects
Chronic inflammatory demyelinating polyneuropathy ,Seronegative immune-mediated neuropathy ,Autoimmune nodopathies ,Therapeutic plasma exchange ,B-cell suppression ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Immune-mediated peripheral neuropathies are heterogeneous group of disorders due to the present of autoantibodies against peripheral nerve molecules located in node of Ranvier such as gangliosides and cell adhesion proteins or myelin components of peripheral nerves. Although the exact aetiology and pathophysiological mechanisms involved are not fully understood, both humoral and cellular immunity are likely playing a role in their pathogenesis. A proportion of patients present with clinical phenotype of rapidly progressive neuropathy refractory to conventional therapies but are lacking in identifiable or detectable antibodies. This makes diagnosis and treatment decision challenging.We illustrate a patient with rapidly progressive seronegative immune-mediated neuropathy resembling autoimmune nodopathy (AN) associated with atypical features (prominent ataxia) and cranial involvement (facial and oropharyngeal weakness, dysgeusia), refractory to conventional therapies (IV immunoglobulin and corticosteroids) but responded to ‘remove and suppress’ treatment regime using therapeutic plasma exchange (TPE), followed by long-term B-cell suppressive therapy.
- Published
- 2024
- Full Text
- View/download PDF
49. TPE in Rennes Hospital (COMPLASMA)
- Published
- 2023
50. Therapeutic plasma exchange in the treatment of COVID-19 induced cytokine storm: the first Moroccan experience
- Author
-
Mohamed Zakaria Bouayed, Ilyass Laaribi, Iliass Benaini, Asmae Yeznasni, Sara Berrajaa, Younes Oujidi, Houssam Bkiyar, Naima Abda, and Brahim Housni
- Subjects
COVID-19 ,Cytokine storm ,Therapeutic plasma exchange ,Intensive care ,Mortality ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Introduction COVID-19 induced cytokine storm is a well-documented phenomena that contributes significantly in the disease’s evolution and prognosis. Therefore, therapies such as therapeutic plasma exchange, constitute a mainstay of therapeutic management especially for critically-ill patients. Methods We conducted a monocentric retrospective cohort study in the Resuscitation Department of the Mohammed VI University Hospital of Oujda-Morocco, to evaluate the efficiency of therapeutic plasma exchange on critically-ill COVID-19 patients over a 6 months period. We divided our patients into two groups: patients who received TPE (Therapeutic Plasma Exchange) sessions (TPE group) and patients who only benefited from the standard protocol treatment (non TPE group). Results Our study included a total of 165 patients, 34.5% of which benefited from TPE sessions. We observed an improvement of oxygenation parameters (SpO2 and PaO2/FiO2 ratio) and a progressive respiratory weaning, as well as a significant decrease of biomarkers indicative of inflammation (lymphocyte count, CRP (C Reactive Protein), IL-6, Ferritin) and coagulopathy (d-dimers, fibrinogen) in the TPE group after 5 consecutive TPE sessions. In comparison with the non-TPE group, The TPE-group patients had a shorter ICU (Intensive Care Unit) length of stay, required less frequently mechanical ventilation, and we more likely to be extubated. Furthermore, the TPE group had a lower mortality rate. Discussion Multiple studies have reported the safety and efficiency of therapeutic plasma exchange in the COVID-19 induced cytokine storm. Given the urgent character of the pandemic at the time, each center followed its own protocol in implementing plasma exchange. Conclusion Similar to the results reported in the literature, our study reports positive results after using TPE specifically in terms of respiratory weaning and an improvement of the cytokine storm biomarkers, and more importantly a lower mortality rate.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.